NCCAM Targets Probiotics, Vitamin E, Curcumin, Devil’s Claw as Priorities for Large-Scale Trials
“While there are many areas of research with scientific promise and potential, NCCAM is currently accepting applications with an emphasis on [these] high-priority topics for CAM clinical research," NCCAM stated.
In an October update, the National Institutes of Health’s National Center for Complementary and Alternative Medicine (NCCAM) highlighted what it deems as priority areas of consideration for large-scale clinical trials. NCCAM says that it is currently accepting applications for research related to probiotics, curcumin, devil’s claw, and vitamin E.
- Specifically for probiotics, NCCAM is considering research looking at biomarkers, safety, and appropriate dosage related to: 1) gut-barrier function in infants and children, 2) preventing antibiotic-induced diarrhea and enhancing influenza vaccine activity, 3) metabolic syndrome, and 4) atopic dermatitis or bacterial vaginosis.
- For curcumin (Curcuma longa), NCCAM is targeting: 1) the bioavailability and effects of curcumin on musculoskeletal pain, and 2) effects on inflammatory bowel disorders. For devil’s claw (Harpagophytum procumbens), NCCAM is interested in effects on musculoskeletal pain. It also identifies butterbur (Petasites hybridus) as being of interest for migraines.
- Finally, for vitamin E, NCCAM describes interest in effects on non-alcoholic steatohepatitis or non-alcoholic fatty liver disease.
“While there are many areas of research with scientific promise and potential, NCCAM is currently accepting applications with an emphasis on [these] high-priority topics for CAM clinical research. Investigators interested in pursuing other areas of research should consult the other funding opportunities available,” NCCAM stated in its update.
Nutritional Outlook thanks Harry Rice, PhD, for the tip.
The Nutritional Outlook Podcast Episode 29: 2024 Ingredients to Watch
January 31st 2024Nutritional Outlook interviews Scott Dicker, market insights director from market researcher SPINS, about ingredients and product categories nutraceutical and nutrition product manufacturers should watch in 2024.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.
